# A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

> **NCT06202261** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 154 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Recurrent Breast Cancer
- Advanced Malignancies

## Interventions

- **DRUG:** TQB2930 for injection
- **DRUG:** Paclitaxel for injection (albumin-bound)
- **DRUG:** TQB3616 capsule
- **DRUG:** Fulvestrant injection
- **DRUG:** Capecitabine tablets
- **DRUG:** Vinorelbine tartrate injection
- **DRUG:** Eribulin mesylate injection
- **DRUG:** gemcitabine hydrochloride for injection

## Key facts

- **NCT ID:** NCT06202261
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-13
- **Primary completion:** 2026-12
- **Final completion:** 2027-10
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202261, "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06202261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*